1. Introduction {#S1}
===============

Stress is well established to influence feeding behaviors and metabolism in both humans and rodents ([@R27]). Corticotropin-releasing factor (CRF) plays a key role in coordinating the hormonal, autonomic, behavioral and visceral components of the acute stress response ([@R38]). In rodents, CRF administered into the brain induces stress-like behaviors, including increased anxiety-like manifestations and food intake suppression ([@R40]; [@R54]). Urocortin 1 (UCN1) is a member of the mammalian CRF-related peptide that is mainly localized in the Edinger--Westphal nucleus, and to a lesser extent, in the olfactory bulb, supraoptic nucleus, ventromedial hypothalamus (VMH) and lateral hypothalamic area ([@R19]; [@R33]). Evidence suggests that experimental stressors activate UCN1 neurons in the Edinger-Westphal nucleus ([@R14]). Both CRF and UCN1 mediate their actions through the activation of CRF receptor subtypes 1 and 2 (CRF~1~ and CRF~2~, respectively); however, CRF and UCN1 exhibit differential binding affinities. UCN1 displays high affinity to both CRF receptor subtypes, while CRF is a preferential CRF~1~ agonist and has a low affinity to CRF~2~ ([@R48]).

It is well documented that UCN1 injected intracerebroventricularly (ICV) is more potent than CRF to suppress fasting- or dark phase-induced food intake without inducing conditioned taste aversion or visceral illness in rodents ([@R4]; [@R35]; [@R36]). ICV UCN1-induced food intake inhibition action is mediated mainly through the activation of brain CRF~2~ in rats ([@R35]; [@R52]). Several brain sites expressing high density of CRF~2~ ([@R6]) and regulate the autonomic nervous system (ANS) ([@R32]) have been identified to be responsive to UCN1, which results in a CRF~2~-mediated anorexigenic response in rats, namely the lateral septum ([@R2]), paraventricular nucleus of the hypothalamus (PVN) ([@R9]), VMH ([@R8]; [@R26]), and dorsal raphe ([@R51]). In addition, based on the observation that UCN1 injected into the fourth brain ventricle is still able to reduce food intake in chronically decerebrated rats ([@R11]), hindbrain structures are believed to be involved in this response. This is consistent with the earlier report that the nucleus tractus solitarius (NTS) is a brainstem site that is responsive to UCN1 ([@R15]).

Several potential mechanisms could participate in the anorexic effects of ICV UCN1. The ICV injection of UCN1 induces a CRF~2~-mediated inhibition of gastric emptying ([@R22]; [@R52]) and hyperglycemia ([@R15]) in rodents. Both effects are known to reduce feeding ([@R7]; [@R29]). In addition, we have recently reported that UCN1 ICV acts through the CRF~2~ receptor to decrease circulating acylated ghrelin ([@R52]), which is the only known orexigenic hormone that is produced peripherally by gastric endocrine X/A cells but acts centrally ([@R18]; [@R24]). Of functional relevance, we have shown that the exogenous injection of ghrelin or the ghrelin enhancer rikkunshito ([@R42]) restored food intake in ICV UCN1-injected rats ([@R52]). However, the mechanism(s) through which the circulating ghrelin is suppressed by the central administration of UCN1 is yet to be elucidated. Changes in the ANS activity influence gastric ghrelin secretion ([@R17]), and various local classical neurotransmitters and neuropeptides are reportedly to influence ghrelin release ([@R13]; [@R37]). Previous reports indicate that centrally injected UCN1 effects on gastric function involve the ANS ([@R10]; [@R12]).

In the present study, we first delineated the ANS pathway(s) that contributes to the decreased circulating ghrelin induced by ICV injection of UCN1 in rats. This was achieved by surgical approach (vagotomy) and mapping the induction of *c-fos* gene expression as a marker of neuronal activation ([@R20]), in specific hypothalamic (PVN, VMH) and brainstem \[LC (locus coeruleus), NTS, DMN (dorsal motor nucleus), RVLM (rostral ventrolateral medulla)\] nuclei that regulate the ANS ([@R32]; [@R44]; [@R45]). Then, we assessed the related peripheral adrenergic mechanisms using the pharmacological blockade of central and peripheral α- and β-adrenergic receptors (ARs). Lastly, we examined the functional implications of ghrelin suppression in the inhibition of food intake induced by ICV UCN1 using blockade of identified AR pathways alone or in combination with a ghrelin receptor antagonist or the ghrelin enhancer, rikkunshito ([@R42]).

2. Materials and methods {#S2}
========================

2.1. Animals {#S3}
------------

Eight-week-old male Sprague-Dawley rats (weight, 240--280g) were purchased from Japan SLC, Inc. (Shizuoka, Japan). All animals were housed in polycarbonate cages in room with controlled conditions of ambient temperature (23 ± 3°C), humidity (50 ± 20%), and lighting (12-h light:dark cycle starting at 7:00 PM). Animals were maintained with water and standard laboratory food *ad libitum*. Access to the standard laboratory food was removed 16 h before experiments, which were conducted between 1 and 5 h after the beginning of the light cycle to avoid the influences of diurnal rhythms. All experimental procedures were performed according to the Guidelines for the Care and Use of Laboratory Animals and approved by the Laboratory Animal Committee of Tsumura & Co. (Tokyo, Japan).

2.2. Surgery {#S4}
------------

### 2.2.1. Intracerebroventricular cannula {#S5}

Rats under sodium pentobarbital (50 mg/kg, intraperitoneal, IP) anesthesia were placed on a stereotaxic apparatus (Japan SLC Inc., Shizuoka, Japan). A stainless steel guide cannula (AG-8; Eicom, Kyoto, Japan) was implanted into the right lateral ventricle using the following coordinates derived from the rat brain atlas ([@R28]): 0.8 mm posterior and 1.4 mm lateral from the bregma and 3.4 mm ventral from the skull surface. Rats were singly housed after the surgery and had at least a recovery period of 5 days before the start of the treatment.

### 2.2.2. Subdiaphragmatic vagotomy {#S6}

The surgery was performed at least 10 days after ICV cannulation as previously described ([@R17]; [@R43]) in pentobarbital-anesthetized rats (40 mg/kg, IP). Following a laparotomy, both vagal trunks located at the lower esophagus were resected, and a pyloroplasty was performed to widen the pylorus and prevent pyloric stenosis. Sham operations consisted of the opening of the abdomen and exposure of the internal organs. The abdomen was closed by sutures. Animals had at least 6 days of recovery time and maintained under standard *ad libitum* food.

2.3. Drugs and treatments {#S7}
-------------------------

Rat UCN1 was purchased from Peptide Institute, Inc. (Osaka, Japan). Phentolamine hydrochloride (non-selective α-AR antagonist), prazosin hydrochloride (selective α~1~-AR antagonist), yohimbine hydrochloride (selective α~2~-AR antagonist), propranolol (non-selective β-AR antagonist), atenolol (selective β~1~-AR antagonist), ICI-118,551 (selective β~2~-AR antagonist), synephrine (non-selective α-AR agonist), phenylephrine hydrochloride (selective α~1~-AR agonist), clonidine hydrochloride (selective α~2~-AR agonist), isoproterenol hydrochloride (non-selective β-AR agonist), denopamine (selective β~1~AR agonist), and salbutamol (selective β~2~-AR agonist) were all purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). The growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist, \[D-Lys^3^\]-GHRP-6, was purchased from Bachem, Inc. (Torrance, CA, USA). These compounds were dissolved in saline when injected IP and in phosphate-buffered saline (PBS) when injected ICV. Rikkunshito, which is a Japanese kampo medicine, was supplied from Tsumura & Co. (Tokyo, Japan) in the form of a powdered extract obtained by spray-drying a hot water extract mixture of the following eight crude drugs: *Atractylodis lanceae rhizoma* (4.0 g), *Ginseng radix* (4.0 g), *Pinelliae tuber* (4.0 g), *Poria* (4.0 g), *Zizyphi fructus* (2.0 g), *Aurantii nobilis pericarpium* (2.0 g), *Glycyrrhizae radix* (1.0 g), and *Zingiberis rhizoma* (0.5 g). Rikkunshito was dissolved in distilled water for oral administration. Components of rikkunshito for binding assay were dissolved in dimethyl sulfoxide (DMSO, final dilution: 1%). Other analytical reagents were highest-purity commercially available products.

Treatments were performed on lightly hand-restrained rats in the following volumes: 10 µL/rat for ICV injection, 1 mL/kg for IP or intravenous (IV) injection through tail vein, and 10 mL/kg for orogastric administration. Rats were handled daily more than 5 days prior to treatment to minimize stress during the procedure.

2.4. Ghrelin determination {#S8}
--------------------------

Rats were euthanized by decapitation, and trunk blood (approximately 4 mL) was collected in cold polypropylene tubes containing 8.0 mg ethylenediaminetetraacetic acid and 0.8 mg aprotinin. Samples were centrifuged at 10,000 × *g* at 4°C for 3 min. The supernatant was acidified with 1M HCl (1/10 volume) and stored at −80°C until the ghrelin assays were performed. Plasma ghrelin levels were determined using active ghrelin and des-acyl ghrelin Enzyme-Linked Immunoassay Kits (Mitsubishi Chemical Corp., Tokyo, Japan). The detection limits for the acylated and des-acyl ghrelin were 2.7 fmol/mL and 12.3 fmol/mL, respectively. The intraassay coefficients of variation for the acylated and des-acyl ghrelin were 0.8--4.8% and 2.2--5.5%, respectively, and the interassay coefficients of variation for the acylated ghrelin and des-acyl ghrelin were 2.8--6.4% and 1.9--9.0%, respectively.

2.5. Binding affinity of rikkunshito for ARs {#S9}
--------------------------------------------

For the α~2A~-AR binding assay, insect Sf9 cells expressing human recombinant α~2A~-AR were homogenized in modified Tris--HCl buffer and aliquots were incubated with 1 nM \[^3^H\] MK-912 for 60 min at 25 °C. Nonspecific binding was estimated in the presence of 10 µM WB-4101 ([@R47]). For α~2B~-AR, CHO-K1 cells stably transfected with a plasmid encoding human α~2B~-AR were homogenized in modified Tris--HCl buffer using standard techniques and aliquots were incubated with 2.5 nM \[^3^H\] rauwolscine for 60 min at 25°C. Nonspecific binding was estimated in the presence of 10 µM prazosin ([@R46]). For α~2C~-AR, insect Sf9 cells expressing human recombinant α~2C~-AR were homogenized in modified Tris--HCl buffer and aliquot was incubated with 1 nM \[^3^H\] MK-912 for 60 min at 25 °C. Nonspecific binding was estimated in the presence of 10 µM WB-4101 ([@R47]). Radio binding assays for α~1~ and β-AR are detailed in [Supplementary Material 1](#SD1){ref-type="supplementary-material"}. The half-maximal inhibitory concentration (IC~50~) values were determined by nonlinear, least-squares regression analysis using the MathIQ™ statistical software (ID Business Solutions Ltd., Surrey, UK).

[Supplementary Material 1](#SD1){ref-type="supplementary-material"} related to this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.psyneuen.2014.09.003>.

2.6. Experimental protocols {#S10}
---------------------------

All experiments were performed in 16 h-fasted rats with no access to food post ICV injection except otherwise mentioned.

### 2.6.1. *c-Fos* gene expression in rat brain induced by ICV UCN {#S11}

Rats with chronic ICV cannula were injected ICV either with PBS or UCN1 (300 pmol/rat) and were anesthetized 1 h later with sodium pentobarbital (50 mg/kg, IP). The brain was collected and processed for *c-fos* mRNA detected by *in situ* hybridization as detailed previously ([@R52]) ([Supplementary Material 2](#SD2){ref-type="supplementary-material"}). *c-Fos* mRNA-positive cells in the PVN, VMH, LC, NTS, DMN and RVLM were unilaterally counted.

[Supplementary Material 2](#SD2){ref-type="supplementary-material"} related to this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.psyneuen.2014.09.003>.

### 2.6.2. Effects of ICV UCN1 on acylated and des-acyl ghrelin plasma levels in sham or vagotomized rats {#S12}

Chronically ICV cannulated rats with sham or subdiaphragmatic vagotomy performed 6 days earlier were divided into two groups (*n* = 8--10/group) and injected ICV with either PBS or UCN1 (300 pmol/rat). Rats were euthanized by decapitation 2 h after ICV injection. The trunk blood was collected for the determination of acylated and des-acyl ghrelin levels in plasma. The ICV dose of UCN1 was selected, based on our previous dose-response studies showing the maximal suppression of 24-h food intake in rats and reduced fasting ghrelin levels at 1-h and 2-h post-ICV injection compared to ICV PBS ([@R52]).

### 2.6.3. Effects of AR antagonists, agonists or rikkunshito on ICV UCN 1-induced reduction of plasma acylated ghrelin levels {#S13}

Chronically ICV-cannulated rats were divided into five groups (*n* = 8--17/group) and injected ICV with PBS or UCN1 (300 pmol/rat) after the following treatments given either IP 15 min before or ICV simultaneously: saline, non-selective α-AR antagonist (phentolamine, 5 mg/kg, IP or 0.05 mg/rat, ICV), selective α~1~-AR antagonist (prazosin, 5 mg/kg, IP or 0.50 mg/rat, ICV), selective α~2~-AR antagonist (yohimbine, 5 mg/kg, IP or 0.04 mg/rat, ICV). The regimen of AR blockade was based on previous reports ([@R3]; [@R17]). In other sets of experiments, the IP pretreatment were given either 15 min before or simultaneously ICV UCN1 with the following β-AR antagonists: non-selective (propranolol, 3 mg/kg), β~1~-selective (atenolol, 10 mg/kg), or β~2~-selective (ICI-118,551, 0.1 mg/kg) ([@R17]; [@R53]); the following β-AR agonists: non-selective (isoproterenol, 0.1 mg/kg), β~1~-selective (denopamine, 0.1 mg/kg) or β~2~-selective (salbutamol, 0.1 mg/kg); or the following α-AR agonists: non-selective (synephrine, 5 mg/kg), α~1~-selective (phenylephrine, 5 mg/kg), or α~2~-selective (clonidine, 5 mg/kg) ([@R17]). In the last set of study, the following pretreatments were given 1 h before ICV UCN1: orogastric gavage with distilled water (10 mL/kg) or rikkunshito (0.5 g/kg or 1.0 g/kg). This regimen of administration was based on our previous studies ([@R43]; [@R52]). In all experiments, the trunk blood was collected 2 h after the ICV injection to determine the acylated ghrelin levels.

### 2.6.4. Effects of a selective α~2~-AR antagonist on ICV UCN 1-induced reduction of food intake {#S14}

Chronically ICV-cannulated rats were pretreated IP with a selective α~2~-AR antagonist (yohimbine, 5 mg/kg) or vehicle and 15min later injected ICV with UCN1 (300 pmol/rat). To assess the effects of the ghrelin antagonist on the selective α~2~-AR antagonist activities, rats were first injected IP with saline or the selective α~2~-AR antagonist, and 15 min later, rats received an IV injection of either saline or \[D-Lys^3^\]-GHRP-6 (3.7 mg/kg) followed 1 min later by ICV PBS or UCN1 (300 pmol/rat). Preweighed chow was placed in each cage, and the 2-h cumulative food intake was monitored immediately after ICV injection.

2.7. Statistical analysis {#S15}
-------------------------

All values are presented as the mean ± standard error of the mean. Statistical analyses of the mean values of two groups were performed using Student's *t*-test or the Aspin-Welch *t*-test. The mean values of multiple groups were determined by two-way factorial analysis of variance (ANOVA) followed by the Bonferroni *post hoc* test or one-way analysis of variance (ANOVA) followed by Dunnett's test or Steel's test. For all tests, probability (*P*) values of \<0.05 were considered statistically significant.

3. Results {#S16}
==========

3.1. ICV UCN1 injection induces c-fos mRNA expression in specific brain nuclei {#S17}
------------------------------------------------------------------------------

ICV UCN1 (300 pmol/rat) did not influence *c-fos* mRNA expression in the DMN while increasing the number of labeled cells in the PVN, VMH, LC, NTS and RVLM by 16-, 29-, 6-, 37- and 13-fold, respectively, compared with ICV vehicle-injected rats as monitored 1 h after the peptide injection by *in situ* hybridization ([Supplementary Fig. S1](#SD5){ref-type="supplementary-material"} and [Table S1](#SD3){ref-type="supplementary-material"}).

[Supplementary Table S1](#SD3){ref-type="supplementary-material"} and [Fig. S1](#SD5){ref-type="supplementary-material"} related to this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.psyneuen.2014.09.003>.

3.2. Vagotomy did not influence ICV UCN1-induced reduction of plasma acylated and des-acyl ghrelin levels {#S18}
---------------------------------------------------------------------------------------------------------

In the sham-operated, fasted rats, UCN1 (300 pmol/rat, ICV) reduced the plasma levels of acylated and des-acyl ghrelin by 31% and 25%, respectively, compared to ICV vehicle injection as monitored at 2 h after the injection ([Fig. 1A and B](#F1){ref-type="fig"}). Similarly, in the rats with subdiaphragmatic vagotomy, ICV UCN1 significantly decreased plasma acylated and des-acyl ghrelin levels by 41% (*P* \< 0.05) and 33% (*P* \< 0.05), respectively ([Fig. 1A and B](#F1){ref-type="fig"}, *n* = 8--10). The magnitude of the reduction did not significantly differ between the sham and vagotomized groups. It is to note that the vagotomized rats injected ICV with vehicle showed a trend to have an increase in acylated ghrelin (21%) and des-acyl ghrelin (22%), which did not reach significance by using the two-way factorial analysis of variance (ANOVA) followed by the Bonferroni *post hoc* test ([Fig. 1A and 1B](#F1){ref-type="fig"}). As acylated ghrelin is the active form of the peptide that activates GHS-R1a to stimulate food intake ([@R39]), in all subsequent experiments, we limited the plasma determination to the acylated form of ghrelin.

3.3. Effects of IP injection or ICV injection of AR antagonists, agonists or rikkunshito on ICV UCN1-induced decreases in plasma acylated ghrelin {#S19}
-------------------------------------------------------------------------------------------------------------------------------------------------

In IP vehicle-pretreated, fasted rats, ICV UCN1 (300 pmol/rat, *n* = 38) induced a significant, 50--59% reduction of fasted plasma levels of acylated ghrelin compared with ICV vehicle ([Fig. 2A--D](#F2){ref-type="fig"}, *P* \< 0.001, *P* \< 0.01, *P* \< 0.01 and *P* \< 0.05, respectively \[*n* = 8--14\]). IP pretreatment with the non-selective α-AR antagonist (phentolamine) or selective α~2~-AR antagonist (yohimbine) before ICV UCN1 increased significantly and similarly plasma levels of acylated ghrelin compared with those of the vehicle pretreated-plus-ICV UCN1 group (58.5 ± 2.5 fmol/mL, 58.6 ± 4.5 fmol/mL vs. 43.5 ± 4.5 fmol/mL respectively, *P* \< 0.05), while the selective α~1~-AR antagonist (prazosin) had no effect (44.9 ± 3.6 fmol/mL; [Fig. 2A](#F2){ref-type="fig"}). However, in the phentolamine- or yohimbine-pretreated rats, the values remained significantly lower than those of the control group (IP saline + ICV PBS: 85.5 ± 6.7 fmol/mL, Dunnett's test: *P* \< 0.05; [Fig. 2A](#F2){ref-type="fig"}, *n* = 14--17/group). Conversely, the IP injection of the selective α~2~-AR agonist (clonidine, *P* \< 0.01), unlike a non-selective α-AR agonist (synephrine) or a selective α~1~-AR agonist (phenylephrine), further decreased the plasma acylated ghrelin levels induced by ICV UCN1 ([Fig. 2B](#F2){ref-type="fig"}, *n* = 8/group and [Supplementary Fig. S2](#SD6){ref-type="supplementary-material"}, *n* = 8/group). In a preliminarily study, the selective α~2~-AR antagonist did not influence the acylated ghrelin levels in fasted rats. Furthermore, a previous report has shown no significant changes in the fasting levels of ghrelin induced by the non-selective α-AR antagonist phentolamine ([@R17]).

[Supplementary Fig. S2](#SD6){ref-type="supplementary-material"} related to this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.psyneuen.2014.09.003>.

With regard to the influences of β-ARs, we found that the selective β~1~-AR antagonist (atenolol, *P* \< 0.05), but not the non-selective β-AR antagonist (propranolol) or the selective β~2~-AR antagonist (ICI-118,551), further decreased the plasma acylated ghrelin levels induced by ICV UCN1 ([Fig. 2C](#F2){ref-type="fig"}, *n* = 8/group). Conversely, the non-selective β-AR agonist (isoproterenol, *P* \< 0.01) or the selective β~1~-AR agonist (denopamine, *P* \< 0.01), but not the selective β~2~-AR agonist (salbutamol), prevented the decreased plasma acylated ghrelin levels elicited by ICV UCN1, leading to acylated ghrelin values not significantly different from those of ICV saline-treated rats ([Fig. 2D](#F2){ref-type="fig"}, *n* = 8/group).

When injected ICV, the non-selective α-AR antagonist (phentolamine), the selective α~1~-AR antagonist (prazosin) and the selective α~2~-AR antagonist (yohimbine) did not influence the reduction of plasma acylated ghrelin levels induced by ICV UCN1 ([Fig. 3A](#F3){ref-type="fig"}, *n* = 8/group). Lastly, the oral administration of rikkunshito significantly inhibited (*P* \< 0.05) the decreased plasma acylated ghrelin levels when given at 1 g/kg, while at a dose of 0.5 g/kg, it had no effect ([Fig. 3B](#F3){ref-type="fig"}, *n* = 14--16/group).

3.4. Effects of selective α~2~-antagonist (yohimbine) in combination with \[D-Lys^3^\]-GHRP-6 on decreased food intake induced by ICV UCN1 {#S20}
------------------------------------------------------------------------------------------------------------------------------------------

In the control-pretreated rats, ICV UCN1 induced a significant 87% reduction of the cumulative 2-h food intake response to overnight fasting (control: IP saline, IV saline, ICV PBS: 4.9 ± 0.4 g/2 h; IP saline, IV saline, ICV UCN1: 0.7 ± 0.3 g/2 h, *P* \< 0.001; [Fig. 4](#F4){ref-type="fig"}, *n* = 7--8/group). IP pre-treatment with the selective α~2~-AR antagonist (yohimbine) prevented ICV UCN1 inhibitory effects (IP yohimbine, IV saline, ICV UCN1: 3.6 ± 1.0 g/2h, *P* \< 0.05) while not influencing significantly the feeding response to the fast (IP yohimbine, IV saline, ICV PBS: 6.8 ± 1.0 g/2h vs. IP saline, IV saline, ICV PBS: 6.4 ± 0.7 g/2h). \[D-Lys^3^\]-GHRP-6 injected IV did not influence the 2-h cumulative food intake in vehicle-treated control rats while completely blocking the normalization of feeding induced by IP yohimbine in ICV UCN1-treated rats ([Fig. 4](#F4){ref-type="fig"}, *n* = 7--8/group).

3.5. *In vitro* binding assays of rikkunshito components on ARs {#S21}
---------------------------------------------------------------

The AR binding-inhibitory activities (IC~50~) of the crude drug components contained in rikkunshito were tested in transfected cells with human AR subtypes. As shown in [Table 1](#T1){ref-type="table"}, glycycoumarin 6-, 8-shogaol and 10-gingerol, and eudesmol display inhibitory activity to α~2A~-AR and differential activities on α~1~-AR or β~1,3~-AR ([Supplementary Table S2](#SD4){ref-type="supplementary-material"}).

[Supplementary Table S2](#SD4){ref-type="supplementary-material"} related to this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.psyneuen.2014.09.003>.

4. Discussion {#S22}
=============

We found that ICV UCN1 -induced reduction of plasma ghrelin levels was not altered by vagotomy and attenuated by the peripheral blockade of α~2~-AR and restored by the activation of β~1~-AR in rats. Conversely, α~2~-AR agonist and β~1~AR antagonist enhanced the inhibitory effect of ICV UCN1. This α~2~-AR-ghrelin inhibitory pathway has functional relevance since yohimbine prevented the anorexic effect of ICV UCN1 and the α~2~-AR action was abolished by the ghrelin receptor antagonist.

UCN1 injected ICV at 300 pmol/rat reproducibly decreased by 50--59% plasma levels of acylated ghrelin in fasted rats consistent with our previous report ([@R31]; [@R52]). UCN1 action is brain-mediated and does not reflect peptide leakage into the periphery since systemic injection of UCN1 increases the total ghrelin plasma levels in fed rats or had no effect in fasted state ([@R49], [@R50]). It has been well established that the majority of circulating ghrelin is produced by X/A-like cells located in the gastric mucosa, as indicated by the pronounced reduction of circulating ghrelin after gastrectomy ([@R1]; [@R23]). The stomach receive prominent vagal inner-vation through efferent projections from DMN neurons ([@R5]). Central vagal activation ([@R38]) and peripheral acetylcholine administration ([@R34]) reportedly increase ghrelin release, while muscarinic receptor antagonists suppress ghrelin secretion in fasted rats ([@R17]). However, ICV UCN1 action is unlikely to be mediated by alterations of vagal pathway as reported for the inhibitory influence of intracisternally injected UCN1 on gastric emptying in rats ([@R10]). This is supported by the observation that subdiaphragmatic vagotomy did not alter the magnitude of ghrelin decrease induced by ICV UCN1. Moreover *c-fos* mRNA, which is used as a marker of autonomic neuronal activation ([@R20]), was not induced in DMN neurons by ICV UCN1 ([Supplementary Fig. S1](#SD5){ref-type="supplementary-material"} and [Table S1](#SD3){ref-type="supplementary-material"}) as previously observed ([@R52]).

In contrast, there are compelling reports documenting that ICV injection of UCN1 activates the core group of autonomic brain structures regulating sympathetic outflow, namely the PVN, LC, NTS and RVLM, as monitored by the robust induction of Fos immunoreactivity ([@R6]; [@R11]) or *c-fos* gene expression including under similar conditions associated with decreased ghrelin plasma levels ([@R52]) and as well as in the present study ([Supplementary Fig. S1](#SD5){ref-type="supplementary-material"} and [Table S1](#SD3){ref-type="supplementary-material"}). We have previously reported that ICV UCN1-induced decreased circulating levels of acylated ghrelin are mediated by brain CRF~2~ ([@R52]). Other function data support that activation of CRF~2~ in the PVN stimulates sympathetic nerve activity in rat the viscera ([@R21]). These data provide neuroanatomical and functional support for a supra spinal sites of action of ICV UCN1 to activate sympathetic outflow. However, it cannot be ruled out that an additional thoracic site regulating sympathetic nerve ([@R30]) can also be involved in ICV UCN1 action.

Activation of sympathetic pathways release nore-pinephrine from nerve endings that bind to ARs, which are classified into α- and β-ARs based on their responses to various catecholamines. Previous studies in rats have indicated that fasting plasma levels of ghrelin are stimulated by α-AR antagonists and β-AR agonists and inhibited by α-AR agonists ([@R17]). In the present study, a pharmacologic approach using peripheral administered selective α- and β-AR subtype antagonists and agonists revealed that α~2~-AR antagonist and β~1~AR agonist raise, while α~2~-AR agonist and β~1~-AR antagonist further suppress, the lowered ghrelin plasma levels under conditions of ICV UCN1 injection in fasted rats. In support of this assertion, the peripheral injection of the α-AR antagonist, phentolamine, and the selective α~2~-AR antagonist, yohimbine, partially prevented ICV UCN1-induced reduction of plasma acylated ghrelin. Conversely, the activation of α~2~-AR with IP injection of clonidine exerted inhibitory effects, as shown by the dose-related further decreased of ghrelin plasma levels in ICV UCN1-treated rats ([Supplementary Fig. S2](#SD6){ref-type="supplementary-material"}). Although peripherally administered the selective α~2~-AR antagonist yohimbine crosses the blood-brain barrier ([@R41]), however it is likely that yohimbine exerts its action peripherally, because, when administered ICV, this α~2~-AR antagonist did not influence the decreased ghrelin levels in response to ICV UCN1.

Additional pharmacological studies established the specificity toward peripheral α~2~-ARs since under the same conditions, the α~1~-AR antagonist (prazosin) or β-AR antagonists (propanolol or the β~2~-AR antagonist, ICI-118,551) had either no effect or further (the β~1~ -AR antagonist, atenolol) enhanced the inhibitory effects of ICV UCN1. Likewise, the activation of other α- or β-AR subtypes by agonists could not mimic the inhibitory effects of UCN1, as shown by the lack of effect of IP injection of α-AR agonist, synephrine, the α~1~-AR agonist, phenylephrine, or the β~2~-AR agonist, salbutamol. In addition, we showed that the IP injection of non-selective β-AR agonist, isoproterenol or the selective β~1~-AR agonist, denopamine, restored the basal plasma levels of acylated ghrelin in ICV UCN1-injected rats. This may represent a direct action on X/A like cells. This finding is supported by a recent study using a culture ghrelinoma cells line showing that ghrelin release is also stimulated selectively by the activation of β~1~-AR agonist and inhibited by β~1~-AR antagonist, atenonol ([@R53]). Other *in vivo* studies have shown that noradrenalin raises the ghrelin levels measured in effluent of microdialysis probe implanted into the rat gastric submucosa ([@R13]). Additionally, electrically stimulated postganglionic sympathetic axons projecting from the celiac ganglions of rats increases ghrelin release ([@R25]). Taken together, it may be speculated that the α~2~-AR antagonist, yohimbine-induced partial reversal of decreased levels of ghrelin under conditions of sympathetic activation by ICV UCN1 may reflect the balance between the inhibitory and stimulatory action of peripheral α~2~-AR and β~1~-AR activation, respectively. However, the cellular mechanisms by which the peripheral α~2~-ARs contribute to reduce the decline of ghrelin plasma levels in ICV UCN1 -treated rats will require further investigation. The α~2-~AR genes were expressed in the rat stomach under our conditions ([Supplementary Fig. S3](#SD7){ref-type="supplementary-material"}) were consistent with a previous study showing α~2A~-AR, α~2B~-AR and α~2c~-AR mRNA levels in the gastric mucosa of rats with a more abundant expression of the message for α~2A~-AR ([@R16]). This suggests that α~2~-ARs may directly or indirectly regulate gastric ghrelin secretion.

[Supplementary Fig. S3](#SD7){ref-type="supplementary-material"} related to this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.psyneuen.2014.09.003>.

Irrespective of the mechanisms involved, we showed that the α~2~-AR signaling pathway has functional relevance to ghlerin secretion. ICV UCN1 decreased the feeding response to an overnight fast consistent with previous reports ([@R4]; [@R35]; [@R36]; [@R52]). This was prevented by the α~2~-AR antagonist, yohimbine. In addition, the simultaneous administration of a ghrelin receptor antagonist and α~2~-AR antagonist completely abolished the effects achieved by α~2~-AR antagonist administration alone. Likewise, rikkunshito established as an enhancer of endogenous ghrelin secretion ([@R42]) administered orogastrically also increased plasma acylated ghrelin inhibited by ICV UCN1. This was associated with the suppression of the reductions in food intake ([Supplementary Fig. S4](#SD8){ref-type="supplementary-material"}) was consistent with our previous data ([@R52]). We reported recently that the decreased food intake following ICV UCN1 injection was improved by the administration of exogenous acylated ghrelin ([@R52]). Collectively, these findings point to a role of ghrelin receptor activation to restore feeding behavior under conditions of decreased circulating ghrelin induced by ICV UCN1.

[Supplementary Fig. S4](#SD8){ref-type="supplementary-material"} related to this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.psyneuen.2014.09.003>.

Lastly, in order to validate further our hypothesis that the UCN1-induced reduction in food intake involved the activation of peripheral α~2~-ARs, we assessed whether rikkunshito functions as a α~2~-AR antagonist. Rikkunshito is a mixture of herbal ingredients; therefore, in this study, we examined its 34 components using an *in vitro* AR binding assay. We found that several components, namely glycycoumarin, 6- and 8-shogaol, 10-gingerol and eudesmol, functioned as α~2~-AR antagonists. These results suggest that the effects of rikkunshito on decreased food intake in response to ICV UCN1 administration may be induced through the α~2~-AR antagonist property of some of its specific components.

In conclusion, the present findings indicate that ICV UCN1 -induced reduction of fasting plasma levels of acylated ghrelin is independent from the vagus nerve, while it is associated with the activation of specific brain nuclei influencing sympathetic pathways. The peripheral AR effectors mediating ghrelin decline after ICV UCN1 involve the activation of α~2~-ARs and the dampening of β~1~-AR stimulatory effect on ghrelin release. The α~2~-ARs activation and related ghrelin decline contribute to the inhibition of feeding response to a fast induced by ICV UCN1. It suggests that α~2~-AR antagonists may improve alterations of food intake linked with suppression of ghrelin under conditions of brain CRF receptor activation.
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![Effects of vagotomy on ICV UCN1-induced decrease in plasma levels of (A) acylated and (B) des-acyl ghrelin in rats. Sub-diaphragmatic vagotomy with pyloroplasty or sham operation was performed 6 days before the experiments. Rats were euthanized 2 h after ICV vehicle (PBS) or UCN1 (300 pmol/rat) administration, and blood samples were collected. All values are presented as the mean ± standard error of the mean (SEM) (*n* = 8--10/group). Significance was identified using the Bonferroni *post hoc* test following two-way analysis of variance (ANOVA). \**P* \< 0.05 vs. vagotomy + PBS-treated group.](nihms964516f1){#F1}

![Effects of IP pretreatment with (A) α-AR antagonists (*n* = 14--17/group), (B) α-AR agonists (*n* = 8/group), (C) β-AR antagonists (*n* = 8/group), and (D) β-AR agonists (*n* = 8/group) on plasma acylated ghrelin levels inhibited by ICV UCN1 in rats. IP injection was performed 15 min before ICV UCN1 (300 pmol/rat) or vehicle, and trunk blood samples were collected 2 h later. All values are presented as the mean ± SEM. Significance was determined using Student's *t*-test or one-way ANOVA followed by *post hoc* Dunnett's test: \**P* \< 0.05 and \*\**P* \< 0.01 vs. UCN1/saline-treated group.](nihms964516f2){#F2}

![Effects of ICV with (A) selective α-AR antagonists (*n* = 8/group) and (B) orogastric administration of rikkunshito (*n* = 14--16/group) on acylated ghrelin levels inhibited by ICV UCN1 in rats. ICV was performed simultaneously with UCN1 (300 pmol/rat) or vehicle. Distilled water or rikkunshito was orogastrically administered (10 mL/kg) 1 h before ICV injection of PBS or UCN1 (300 pmol/rat), the rats were euthanized 2 h later, and blood samples were collected. All values are presented as the mean ± SEM. Significance was determined using Student's *t*-test or ANOVA followed by *post hoc* Dunnett's tests: \**P* \< 0.05 vs. UCN1 + Distilled water-treated group.](nihms964516f3){#F3}

![Effects of selective α2-AR antagonist (yohimbine) alone or in combination with a ghrelin receptor antagonist on food intake in ICV UCN1-treated rats. Saline or yohimbine (5 mg/kg) was administrated intraperitoneally 15 min before ICV injection of PBS or UCN1 (300 pmol/rat). Saline or \[D-Lys^3^\]-GHRP-6 (3.7 mg/kg) was administrated intravenously into the tail vein 1 min after ICV administration of PBS or UCN1 (300 pmol/rat). Each bar represents the mean ± SEM (*n* = 7--8/group). Significance was determined using Steel's post hoc test following one-way ANOVA analysis \**P* \< 0.05 compared with the UCN1 /saline group. Significance was determined using Aspin-welch *t*-test. +*P* \< 0.05 vs. the UCN1/selective α2-AR antagonist (yohimbine) group. Significance between PBS and UCN1/saline was determined using Student's *t*-test.](nihms964516f4){#F4}

###### 

Binding assays for α~2~-adrenergic receptors by rikkunshito components (IC~50~ values).

  Rikkunshito components                                 α~2~-adrenergic receptor subtypes                             
  -------------------------------- --------------------- ----------------------------------- ------------ ------------ ------------
  *Glysyrrhizae Radix*             Glycycoumarin         5.2 ± 0.7                           39.4 ± 3.3   14.5 ± 0.3   ---
  *Zingiberis*                     6-Shogaol             24.7 ± 2.4                          ---          ---          ---
  *Rhizoma*                        8-Shogaol             5.7 ± 0.8                           ---          6.1 ± 0.5    ---
                                   10-Gingerol           5.4 ± 0.2                           30.9 ± 1.9   6.6 ± 0.8    ---
  *Aurantii Nobilis*               Heptamethoxyflavone   ---                                 ---          ---          ---
  *pericarpium*                    Synephrine            ---                                 ---          ---          11.2 ± 1.2
  *Atractylodis Lanceae Rhizoma*   Eudesmol              37.2 ± 4.4                          ---          ---          ---

(−): Indicates more than 100 µmol/Las IC~50~ values.

NS: Non selective.

Each value indicates the mean ± SEM of three samples as µmol/L
